Physician profile
Richard A Adler
NPI 1629076179
$2,737,297.45
in general payments reported to CMS, 2019-2025
22 companies · $241K in 2025
The $241K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301K · 2020: $268K · 2021: $303K · 2022: $457K · 2023: $528K · 2024: $639K · 2025: $241K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $782K · Travel and Lodging: $198K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $160K · Consulting Fee: $126K · Honoraria: $116K · Food and Beverage: $27K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $781,668.69 |
| Travel and Lodging | $197,516.23 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $159,900.00 |
| Consulting Fee | $125,966.13 |
| Honoraria | $115,949.00 |
| Food and Beverage | $27,002.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $772,778.42 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $441,745.34 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Tarsus Pharmaceuticals, INC. | $321,854.72 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $217,628.96 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $197,009.41 | 2024-2025 | Vevye, Triesence |
| Bausch & Lomb Americas INC. | $192,160.81 | 2023-2025 | Miebo, Xiidra, Blink Nutritears |
| Lumenis Be INC | $166,176.87 | 2021-2025 | M22, Optilight |
| Lumenis, INC | $134,997.40 | 2019-2021 | |
| Abbvie INC. | $116,208.58 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Kala Pharmaceuticals, INC. | $85,788.82 | 2020-2022 | |
| Alcon Vision LLC | $55,448.83 | 2024-2025 | Tryptyr, Rocklatan |
| Lumenis Ltd. | $9,000.00 | 2019-2020 | |
| Lumenis Be Ltd | $8,000.00 | 2021-2022 | |
| Lumenis (Germany) Gmbh | $6,000.00 | 2019-2022 | |
| Thea Pharma INC. | $3,281.86 | 2022-2023 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $3,000.00 | 2024-2025 | Tryptyr |
| Lumenis Be Anz Pty Ltd | $2,549.00 | 2023 | Optilight |
| Lumenis (Australia) Pty. Ltd. | $2,000.00 | 2020 | |
| Aerie Pharmaceuticals, INC. | $1,600.00 | 2021 | |
| Integra Lifesciences Corporation | $33.25 | 2023 | Durasorb Monofilament Mesh |
| Eyevance Pharmaceuticals LLC | $17.67 | 2022 | |
| Dompe US, INC. | $17.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.